Background: and Purpose Treatments for neuromyelitis optica spectrum disorder (NMOSD) such as eculizumab, ravulizumab, satralizumab, and inebilizumab have significantly advanced relapse prevention, but they remain expensive. Rituximab is an off-label yet popular alternative that offers a cost-effective solution, but its real-world efficacy needs better quantification for guiding the application of newer approved NMOSD treatments (ANTs). This study aimed to determine real-world rituximab failure rates to anticipate the demand for ANTs and aid in resource allocation. Methods: We conducted a nationwide retrospective study involving 605 aquaporin-4-antibody-positive NMOSD patients from 22 centers in South Korea that assessed the efficacy and safety of rituximab over a median follow-up of 47 months. Results: The 605 patients treated with rituximab included 525 (87%) who received continuous therapy throughout the follow-up period (median=47 months, interquartile range=15–87 months). During this period, 117 patients (19%) experienced at least 1 relapse. Notably, 68 of these patients (11% of the total cohort) experienced multiple relapses or at least 1 severe relapse.Additionally, 2% of the patients discontinued rituximab due to adverse events, which included severe infusion reactions, neutropenia, and infections. Conclusions This study has confirmed the efficacy of rituximab in treating NMOSD, as evidenced by an 87% continuation rate among patients over a 4-year follow-up period. Nevertheless, the occurrence of at least one relapse in 19% of the cohort, including 11% who experienced multiple or severe relapses, and a 2% discontinuation rate due to adverse events highlight the urgent need for alternative therapeutic options.

Background: and Purpose Treatments for neuromyelitis optica spectrum disorder (NMOSD) such as eculizumab, ravulizumab, satralizumab, and inebilizumab have significantly advanced relapse prevention, but they remain expensive. Rituximab is an off-label yet popular alternative that offers a cost-effective solution, but its real-world efficacy needs better quantification for guiding the application of newer approved NMOSD treatments (ANTs). This study aimed to determine real-world rituximab failure rates to anticipate the demand for ANTs and aid in resource allocation. Methods: We conducted a nationwide retrospective study involving 605 aquaporin-4-antibody-positive NMOSD patients from 22 centers in South Korea that assessed the efficacy and safety of rituximab over a median follow-up of 47 months. Results: The 605 patients treated with rituximab included 525 (87%) who received continuous therapy throughout the follow-up period (median=47 months, interquartile range=15–87 months). During this period, 117 patients (19%) experienced at least 1 relapse. Notably, 68 of these patients (11% of the total cohort) experienced multiple relapses or at least 1 severe relapse.Additionally, 2% of the patients discontinued rituximab due to adverse events, which included severe infusion reactions, neutropenia, and infections. Conclusions This study has confirmed the efficacy of rituximab in treating NMOSD, as evidenced by an 87% continuation rate among patients over a 4-year follow-up period. Nevertheless, the occurrence of at least one relapse in 19% of the cohort, including 11% who experienced multiple or severe relapses, and a 2% discontinuation rate due to adverse events highlight the urgent need for alternative therapeutic options.

Background: and Purpose Treatments for neuromyelitis optica spectrum disorder (NMOSD) such as eculizumab, ravulizumab, satralizumab, and inebilizumab have significantly advanced relapse prevention, but they remain expensive. Rituximab is an off-label yet popular alternative that offers a cost-effective solution, but its real-world efficacy needs better quantification for guiding the application of newer approved NMOSD treatments (ANTs). This study aimed to determine real-world rituximab failure rates to anticipate the demand for ANTs and aid in resource allocation. Methods: We conducted a nationwide retrospective study involving 605 aquaporin-4-antibody-positive NMOSD patients from 22 centers in South Korea that assessed the efficacy and safety of rituximab over a median follow-up of 47 months. Results: The 605 patients treated with rituximab included 525 (87%) who received continuous therapy throughout the follow-up period (median=47 months, interquartile range=15–87 months). During this period, 117 patients (19%) experienced at least 1 relapse. Notably, 68 of these patients (11% of the total cohort) experienced multiple relapses or at least 1 severe relapse.Additionally, 2% of the patients discontinued rituximab due to adverse events, which included severe infusion reactions, neutropenia, and infections. Conclusions This study has confirmed the efficacy of rituximab in treating NMOSD, as evidenced by an 87% continuation rate among patients over a 4-year follow-up period. Nevertheless, the occurrence of at least one relapse in 19% of the cohort, including 11% who experienced multiple or severe relapses, and a 2% discontinuation rate due to adverse events highlight the urgent need for alternative therapeutic options.

Purpose: This study aimed to examine changes in nurse staffing grades and nursing fee revenues following the third amendment of the resource-based relative value scale, implemented in January 2024. Methods: Revised nurse staffing grades were determined based on the number of patients per nurse (PpN), calculated by dividing the daily patient census by the number of registered nurses working in general wards. Changes in staffing grades were analyzed from the fourth quarter of 2023 to the first quarter of 2024 among 44 tertiary hospitals, 328 general hospitals, and 1,378 non-general hospitals. Results: In 2024, the previous "best grade" (grade 1) was subdivided into two or three grades. The best grade was redefined as grade S (PpN<1.5) in tertiary and general hospitals and grade A (PpN<2.0) in non-general hospitals. By 2024, 72.4%, 11.8%, and 22.5% of tertiary, general, and non-general hospitals, respectively, achieved the best grade. The estimated additional annual nursing fee revenues per nurse in 2024 (compared to 2023) for hospitals advancing from grade 1 to grade S ranged from 1,088,455 to 11,412,655 KRW in tertiary hospitals and 11,483,834 KRW in general hospitals. Conclusion To ensure appropriate nurse staffing levels, nursing fees should be proportionally differentiated based on staffing requirements. Additional revenues should be strategically allocated to enhance nurse compensation, thereby improving workforce sustainability and care quality.

Purpose: This study aimed to examine changes in nurse staffing grades and nursing fee revenues following the third amendment of the resource-based relative value scale, implemented in January 2024. Methods: Revised nurse staffing grades were determined based on the number of patients per nurse (PpN), calculated by dividing the daily patient census by the number of registered nurses working in general wards. Changes in staffing grades were analyzed from the fourth quarter of 2023 to the first quarter of 2024 among 44 tertiary hospitals, 328 general hospitals, and 1,378 non-general hospitals. Results: In 2024, the previous "best grade" (grade 1) was subdivided into two or three grades. The best grade was redefined as grade S (PpN<1.5) in tertiary and general hospitals and grade A (PpN<2.0) in non-general hospitals. By 2024, 72.4%, 11.8%, and 22.5% of tertiary, general, and non-general hospitals, respectively, achieved the best grade. The estimated additional annual nursing fee revenues per nurse in 2024 (compared to 2023) for hospitals advancing from grade 1 to grade S ranged from 1,088,455 to 11,412,655 KRW in tertiary hospitals and 11,483,834 KRW in general hospitals. Conclusion To ensure appropriate nurse staffing levels, nursing fees should be proportionally differentiated based on staffing requirements. Additional revenues should be strategically allocated to enhance nurse compensation, thereby improving workforce sustainability and care quality.

Purpose: This study aimed to examine changes in nurse staffing grades and nursing fee revenues following the third amendment of the resource-based relative value scale, implemented in January 2024. Methods: Revised nurse staffing grades were determined based on the number of patients per nurse (PpN), calculated by dividing the daily patient census by the number of registered nurses working in general wards. Changes in staffing grades were analyzed from the fourth quarter of 2023 to the first quarter of 2024 among 44 tertiary hospitals, 328 general hospitals, and 1,378 non-general hospitals. Results: In 2024, the previous "best grade" (grade 1) was subdivided into two or three grades. The best grade was redefined as grade S (PpN<1.5) in tertiary and general hospitals and grade A (PpN<2.0) in non-general hospitals. By 2024, 72.4%, 11.8%, and 22.5% of tertiary, general, and non-general hospitals, respectively, achieved the best grade. The estimated additional annual nursing fee revenues per nurse in 2024 (compared to 2023) for hospitals advancing from grade 1 to grade S ranged from 1,088,455 to 11,412,655 KRW in tertiary hospitals and 11,483,834 KRW in general hospitals. Conclusion To ensure appropriate nurse staffing levels, nursing fees should be proportionally differentiated based on staffing requirements. Additional revenues should be strategically allocated to enhance nurse compensation, thereby improving workforce sustainability and care quality.

Purpose: This study aimed to examine changes in nurse staffing grades and nursing fee revenues following the third amendment of the resource-based relative value scale, implemented in January 2024. Methods: Revised nurse staffing grades were determined based on the number of patients per nurse (PpN), calculated by dividing the daily patient census by the number of registered nurses working in general wards. Changes in staffing grades were analyzed from the fourth quarter of 2023 to the first quarter of 2024 among 44 tertiary hospitals, 328 general hospitals, and 1,378 non-general hospitals. Results: In 2024, the previous "best grade" (grade 1) was subdivided into two or three grades. The best grade was redefined as grade S (PpN<1.5) in tertiary and general hospitals and grade A (PpN<2.0) in non-general hospitals. By 2024, 72.4%, 11.8%, and 22.5% of tertiary, general, and non-general hospitals, respectively, achieved the best grade. The estimated additional annual nursing fee revenues per nurse in 2024 (compared to 2023) for hospitals advancing from grade 1 to grade S ranged from 1,088,455 to 11,412,655 KRW in tertiary hospitals and 11,483,834 KRW in general hospitals. Conclusion To ensure appropriate nurse staffing levels, nursing fees should be proportionally differentiated based on staffing requirements. Additional revenues should be strategically allocated to enhance nurse compensation, thereby improving workforce sustainability and care quality.

Background: Genetic studies are clinically recommended in some cases of inherited arrhythmia syndromes. Nextgeneration sequencing (NGS) would be helpful because of its high analytical throughput and relative speed. This study aimed to assess the mutation-detection yield obtained by NGS compared with conventional Sanger sequencing method. Methods: Patients with aborted sudden cardiac death and their families who underwent gene sequencing tests for inherited arrhythmia syndromes were retrospectively and enrolled in this study from 2017 to 2022 at Chonnam National University Hospital. We evaluated NGS study results of 17 patients (NGS group) and Sanger study results of 19 patients (Sanger group). Results: 64.7% of NGS and 94.7% of Sanger group were probands. Type 1 Brugada pattern ECG was more frequent in NGS group (64.7% vs. 21.1%; p = 0.007). BrS was the most common disorder in NGS group (76.5%), and idiopathic ventricular fibrillation was the most common one in Sanger group (63.2%). Mutations with uncertain significance were the most common ones in NGS group (89.5%), and pathogenic or likely pathogenic mutations were the most common ones in Sanger group (45.7%). When positive yield was defined as the ratio of pathogenic or likely pathogenic mutations that were detected by sequencing, the yields were 10.5% and 45.7% in NGS and Sanger groups, respectively. The NGS arrhythmia panel did not cover two inherited arrhythmia-related mutations (RYR1, APOA5) that were detected by the Sanger method. The extended NGS arrhythmia panel was able to detect 84.8% of inherited arrhythmia-related mutations that were detected in Sanger group. Conclusions NGS study has some limitations in obtaining the full genetic data of probands. Well-designed NGS panels are needed to increase the efficiency of the NGS study. With the well-designed panels, large-scale gene sequencing can efficiently and rapidly be applied in real clinical practices, especially in inherited fatal arrhythmia syndromes that have a high detection yield in genetic analyses.

PURPOSE: To evaluate the clinical efficacy of real-time sonoelastography (RTS) for the follow-up of congenital muscular torticollis, based on measurements of muscle elasticity. MATERIALS AND METHODS: Thirty-four infants (23 male, 11 female) with congenital sternocleidomastoid (SCM) muscle torticollis underwent ultrasonography and elastography between November 2012 and December 2014. We evaluated the thickness, morphology (mass-like, fusiform, or overall thickened shape), and echogenicity of the SCM muscle on grayscale images and color patterns (homogeneous blue, mixed green < 50% and ≥ 50%, and green to red) on elastography. Strain ratios were measured using Q-lab software. A clinician classified the degree of neck rotation and side flexion deficits using a 5-point grade system based on angles of neck rotation and side flexion. Correlations between the ultrasonography and clinical findings were evaluated by statistical analysis. RESULTS: Twenty-two infants had right and 12 had left SCM torticollis, respectively. Linear regression analysis showed that involved/contralateral SCM thickness differences, morphology, elasticity color scores, and strain ratios of the affected SCM muscles were significantly correlated with neck rotation and side flexion deficit scores (p < 0.05). The elasticity color score of the affected SCM muscle was the most significant factor. CONCLUSION RTS might provide a reliable means for evaluating and monitoring congenital muscular torticollis.